

**Amendments to the Claims**

Please cancel Claims 35, 37, 39, 42, 44-55 and 59-64. Please amend Claims 1, 36, 38, 40, 41, 43 and 56-58. Support for the amendments to Claim 1 can be found, for example, at p. 3, line 9, p. 18, lines 26-27, and p. 35 (for “intravenously”); at p. 35, lines 17-18 (for “biweekly”); and at p. 32, lines 1-2 and lines 31-33 (for reduction of accumulated glycogen and/or arrest of further accumulation of glycogen). Support for the representative amount, 20 mg/kg, in Claim 36 is set forth for example at p. 19, line 7. The remainder of the claims have been amended to correct dependency. No new matter has been added.

Add Claims 65-67. Support for these added claims is found, for example, at page 3, lines 12-14. No new matter has been added.

The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

1. (Currently Amended) A method of treating a human patient with Pompe’s disease, comprising: intravenously administering biweekly to the patient a therapeutically effective amount of human acid alpha glucosidase, whereby the concentration of accumulated glycogen is reduced and/or further accumulation of glycogen is arrested.
- 2-35. (Canceled)
36. (Currently Amended) The method of claim ~~35~~ 1, wherein the patient is administered at least ~~60~~ 20 mg/kg body weight per week.
37. (Canceled)
38. (Currently Amended) The method of claim ~~35~~ 1, wherein the patient is administered a single dosage of alpha-glucosidase per week.
39. (Canceled)

40. (Currently Amended) The method of claim 35 1, wherein the amount is administered per week for a period of at least 24 weeks.
41. (Currently Amended) The method of claim 35 1, wherein the alpha-glucosidase is administered intravenously.
42. (Canceled)
43. (Currently Amended) The method of claim 35 1, wherein the alpha-glucosidase is predominantly in a 110 kD form.
- 44-55. (Canceled)
56. (Currently Amended) The method of claim 35 1, wherein the dosage is at least 40 mg/kg body weight per week.
57. (Currently Amended) The method of claim 35 1, further comprising detecting a reduction in hypertrophic cardiomyopathy responsive to the administering.
58. (Currently Amended) The method of claim 35 1, further comprising detecting increased alpha-glucosidase activity in muscle responsive to the administering.
- 59-64. (Canceled)
65. (New) The method of claim 1, wherein the Pompe's disease is infantile Pompe's disease.
66. (New) The method of claim 1, wherein the Pompe's disease is juvenile Pompe's disease.
67. (New) The method of claim 1, wherein the Pompe's disease is adult Pompe's disease.